trending Market Intelligence /marketintelligence/en/news-insights/trending/ra_cmgrjxij_lyfd83yitw2 content esgSubNav
In This List

Roche hemophilia drug Hemlibra wins EU nod

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Roche hemophilia drug Hemlibra wins EU nod

The European Commission approved Swiss group Roche Holding AG's hemophilia A drug Hemlibra to treat patients who have developed resistance to other treatments.

Hemophilia A is an inherited disorder in which a person's blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. People with the disorder either lack or do not have enough of a clotting protein called factor VIII.

Hemlibra, or emicizumab, aims to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A with antibodies that block factor VIII replacement therapies.

The approval was backed by data from two clinical trials.

In the first trial, Hemlibra cut the bleed rate by 87% in adults and adolescents with the disease versus those who did not receive treatment. In the second trial, 87% of the children taking the drug did not experience a bleeding episode that required treatment.

Hemlibra is already approved in the U.S.